Tardive Dyskinesia Market Projected to Reach USD 4.4 Billion by 2036, Growing at 8.1% CAGR Amid Pipeline Innovation
核心洞察
The global tardive dyskinesia (搜索) market across the 7MM was valued at USD 4.4 billion in 2025, with the United States accounting for approximately 98% of the total market share.
Currently approved VMAT2 (搜索) inhibitors valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO XR) remain the standard of care, though they address symptoms without reversing underlying neurobiological dysfunction.
Emerging therapies including NBI-1065890, SOM3355, LY03015, and ACP-271 (搜索) are advancing through clinical development, with Neurocrine's NBI-1065890 in Phase II as the most advanced pipeline asset.
The tardive dyskinesia (搜索) (TD) therapeutics market is poised for significant expansion, with DelveInsight projecting a compound annual growth rate (CAGR) of 8.1% during the forecast period from 2026 to 2036. The market, valued at USD 4.4 billion across the seven major markets (7MM) in 2025, is being propelled by improved diagnosis, treatment advancements, aging demographics, increased awareness, and the anticipated launch of multiple emerging therapies.
The United States dominates the treatment landscape, accounting for approximately 98% of the total market size across the 7MM in 2025, which also includes the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2025, the total number of prevalent cases of tardive dyskinesia (搜索) across the 7MM was approximately 1.7 million, with the US representing roughly 40% of the population receiving three or more months of antipsychotic therapy.
Current Standard of Care and Its Limitations
Currently approved vesicular monoamine transporter 2 (VMAT2 (搜索)) inhibitors — valbenazine (INGREZZA) and deutetrabenazine (AUSTEDO XR) — represent the standard of care for tardive dyskinesia (搜索). These agents have demonstrated significant efficacy in reducing abnormal involuntary movements while maintaining psychiatric stability in most patients. However, the market remains heavily dominated by VMAT2 inhibitor-based therapies, reflecting limited mechanistic diversity.
"Although therapeutic advances have substantially improved symptom management, currently available treatments are primarily symptomatic and do not address or reverse the underlying neurobiological dysfunction associated with chronic dopamine receptor hypersensitivity," according to the DelveInsight analysis.
Existing therapies also carry tolerability and safety limitations, including somnolence, fatigue, akathisia, depression risk, and potential cardiovascular adverse events. These concerns are particularly pronounced among elderly patients and those with multiple comorbidities, underscoring the need for therapies with improved safety profiles.
The Diagnostic Challenge
Underdiagnosis remains a major obstacle in the tardive dyskinesia (搜索) landscape. Involuntary movements characteristic of TD are frequently misattributed to underlying psychiatric disorders, medication-related effects, or normal aging, resulting in delayed diagnosis and treatment initiation. Improved recognition of TD among healthcare providers is contributing to higher diagnosis rates, gradually expanding the treatable patient pool.
Emerging Pipeline and Competitive Landscape
The clinical pipeline for TD, while relatively limited compared with many other central nervous system disorders, features several promising candidates. The majority of investigational agents are in preclinical, Phase I, or Phase II development.
Neurocrine Biosciences' NBI-1065890, currently in Phase II clinical trials, is the most advanced emerging asset. The investigational compound is a potent, selective, and orally bioavailable VMAT2 (搜索) inhibitor designed to regulate dopaminergic signaling and reduce abnormal involuntary movements. Neurocrine initiated the Phase II study in adults with tardive dyskinesia (搜索) in January 2026.
SOM Biotech (搜索)'s SOM3355 is in Phase IIb clinical development and employs a differentiated multimodal mechanism of action, combining selective β1-adrenergic receptor modulation with inhibition of both VMAT1 (搜索) and VMAT2 (搜索). Unlike conventional dopamine-depleting therapies, SOM3355 is intended to reduce involuntary movements while potentially lowering the risk of neuropsychiatric adverse events, including depression, somnolence, anxiety, and akathisia. The candidate is supported by encouraging safety and efficacy data from Huntington's disease studies.
Luye Pharma (搜索) Group's LY03015 represents a novel approach as the world's first investigational drug designed to inhibit VMAT2 (搜索) and activate the sigma-1 receptor (Sigma-1R (搜索)). In April 2026, the company announced enrollment of the first subject in a US pharmacokinetic bridging clinical trial. The candidate is intended for both tardive dyskinesia (搜索) and Huntington's disease.
Acadia Pharmaceuticals' ACP-271 (搜索), an investigational small-molecule therapy currently in Phase I clinical development, is designed to modulate neurological pathways implicated in abnormal involuntary movements. The company expects to initiate its first-in-human clinical study in healthy volunteers during the fourth quarter of 2026.
Additional pipeline candidates include SER-270 (Serina Therapeutics) and TARDOXAL (Medicure).
Aparna Thakur, Project Manager of Forecasting at DelveInsight, noted that "despite a limited pipeline, emerging therapies such as SOM3355 and novel GPR88 agonists offer potential for next-generation tardive dyskinesia (搜索) treatments with improved selectivity, tolerability, and patient adherence."
Recent Clinical Data and Real-World Evidence
In April 2026, Neurocrine Biosciences presented new real-world evidence at the Academy of Managed Care Pharmacy 2026 Annual Meeting demonstrating that adult patients with tardive dyskinesia (搜索) treated with valbenazine showed higher treatment persistence compared to those receiving deutetrabenazine. The following month, the company presented real-world data demonstrating the functional impact associated with mild tardive dyskinesia severity and the clinical improvement observed with valbenazine capsules.
Market Outlook
The anticipated launch of emerging therapies is poised to transform the tardive dyskinesia (搜索) market landscape in the coming years. As these therapies continue to mature and gain regulatory approval, they are expected to reshape treatment paradigms, offering new standards of care and unlocking opportunities for medical innovation. The report highlights a significant unmet need for novel therapeutic approaches capable of benefiting patients who are refractory to, intolerant of, or inadequately controlled with existing treatments, indicating considerable opportunities for future therapeutic development in this space.